Introduction: Infant and young child (IYC) growth impairment remains a public health problem in Africa partly because infants are exposed to staple foods (contaminated with mycotoxins) at an early age. Understanding the role of mycotoxins in IYC growth is vital, and this paper systematically reviews the available knowledge. Methods: Studies were searched and included if they provided information on African IYC mycotoxin exposure rates and/or growth. Studies were excluded if subjects were older than 15 years, if they were animal studies or focusing on other mycotoxins. Relevant search words were included in search strings. Eight reviews were identified and reference lists scrutinised for additional studies. Results: Ten studies were included; 8 focused on aflatoxin (AF), 2 on fumonisin (FB) and none on deoxynivalenol (DON) and zearalenone (ZEA). AF exposure prevalence reached 100% with levels at 40.4 pg/mg. AF was present in umbilical cords indicating that AF crosses the placenta. Maternal exposure levels were correlated with breast milk levels. The highest levels of serum AF (mean 32.8 pg/mg) were measured in Benin and Togo with 5.4% reaching levels higher than 200 pg/mg. At the end of weaning, children had similar prevalence and exposure levels as adults. Results also indicated that infants with higher levels of maternal exposure had significantly lower height-for-age z-scores (HAZ scores), although there was no significant association between cord AF and infant HAZ scores or AF in cord blood and HAZ scores. Significantly higher mean maternal AF levels related to lower weight-for-age z-scores (WAZ scores) were reported, and infants with higher levels of maternal exposure had significantly lower WAZ scores that decreased over age. Cord AF levels had no effect on infant WAZ scores. One study investigated the association between FB and IYC growth and found that those with FB intakes greater than the provisional maximum tolerable daily intake were significantly shorter (1.3 cm) and lighter (328 g). No studies investigated the role of DON and ZEA. Conclusion: A limited number of epidemiological studies have been conducted, and available research indicates extreme exposures to AF. There are strong associations between AF exposure and stunting and wasting. However, more epidemiological research is urgently needed to understand the role of FB, DON and ZEA in IYC growth.

Keywords:
Mycotoxin, Aflatoxin, Fumonisins, Deoxynivalenol, Zearalenone, Stunting, Wasting, Underweight, Africa, Infants
1.
World Health Organization: World Health Statistics 2012. http://www.who.int/gho/publications/world_health_statistics/2012/en/ (accessed March 15, 2014).
2.
Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, Mathers C, Rivera J: Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008;371:243-260.
3.
Wild CP, Gong YY: Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010;31:71-82.
4.
Miller JD: Fungi and mycotoxins in grain - implications for stored-product research. J Stored Prod Res 1995;31:1-16.
5.
Bennett JW, Klich M: Mycotoxins. Clin Microbiol Rev 2003;16:497.
6.
Smith LE, Stoltzfus RJ, Prendergast A: Food chain mycotoxin exposure, gut health and impaired growth: a conceptual framework. Adv Nutr 2012;3:526-531.
7.
Gelderblom WC, Jaskiewicz K, Marasas WFO, Thiel PG, Horak RM, Vleggaar R, Kriek NPJ: Fumonisins - novel mycotoxins with cancer-promoting activity produced by Fusarium moniliforme. Appl Environ Microbiol 1988;54:1806-1811.
8.
Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D: Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004;80:1106-1122.
9.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. Lyon, International Agency for Research on Cancer, 2002.
10.
Shuaib FM, Jolly PE, Ehiri JE, Yatich N, Jiang Y, Funkhouser E, Person SD, Wilson C, Ellis WO, Wang JS, Williams JH: Association between birth outcomes and aflatoxin B1 biomarker blood levels in pregnant women in Kumasi Ghana. Trop Med Int Health 2010;15:160-167.
11.
Gong Y, Cardwell K, Hounsa A, Egal S, Turner PC, Hall AJ, Wild CP: Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. BMJ 2002;325:20-21.
12.
Gong Y, Hounsa A, Egal S, Turner PC, Sutcliffe AE, Hall AJ, Cardwell K, Wild CP: Postweaning exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West Africa. Environ Health Perspect 2004;112:1334-1348.
13.
Polychronaki N, Turner P, Mykkanen H, Gong Y, Amra H, Abdel-Wahhab M, El-Nezami H: Determinants of aflatoxin M1 in breast milk in a selected group of Egyptian mothers. Food Addit Contam 2006;23:700-708.
14.
Polychronaki N, Wild CP, Mykkanen H, Amra H, Abdel-Wahhab M, Sylla A, Diallo M, El-Nezami H, Turner PC: Urinary biomarkers of aflatoxin exposure in young children from Egypt and Guinea. Food Chem Toxicol 2008;46:519-526.
15.
Turner PC, Collinson AC, Cheung YB, Gong Y, Hall AJ, Prentice AM, Wild CP: Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int J Epidemiol 2007;36:1119-1125.
16.
Gong YY, Egal S, Hounsa A, Hounsa A, Turner PC, Hall AJ, Cardwell KF, Wild CP: Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: the critical role of weaning. Int J Epidemiol 2003;32:556-562.
17.
Okoth SA, Ohingo M: Dietary aflatoxin exposure and impaired growth in young children from Kisumu District, Kenya: cross sectional study. Afr J Health Sci 2004;11:43-54.
18.
Weaver VM, Buckley TJ, Groopman JD: Approaches to environmental exposure assessment in children. Environ Health Persp 1998;106:827-832.
19.
Gelderblom WC, Jaskiewicz K, Marasas WFO, Thiel PG, Horak RM, Vleggaar R, Kriek NPJ: Fumonisins - novel mycotoxins with cancer-promoting activity produced by Fusarium moniliforme. Appl Environ Microbiol 1988;54:1806-1811.
20.
Munkvold GP: Cultural and genetic approaches to managing mycotoxins in maize. Ann Rev Phytopathol 2003;41:99-116.
21.
Kimanya ME, De Meulenaer B, Roberfroid D, Lachat C, Kolsteren P: Fumonisin exposure through maize in complementary foods is inversely associated with linear growth of infants in Tanzania. Mol Nutr Food Res 2010;54:1659-1667.
22.
Kimanya ME, De Meulenaer B, Van Camp J, Baert K, Kolsteren P: Strategies to reduce exposure of fumonisins from complementary foods in rural Tanzania. Matern Child Nutr 2012;8:503-511.
23.
Shephard GS, Marasas WFO, Burger HM, Somadyalla NIM, Rheeder JP, Van Der Westhuizen L, Gatyeni P, Van Scalkwyk DJ: Exposure assessment for fumonisins in the former Transkei region of South Africa. Food Addit Contam 2007;1:621-629.
24.
Nkonya E, Xavery P, Akonaay H, Mwangi W, Anandajayasekeram P, Verkuijl H, Martella D, Moshi A: Adoption of maize production technologies in Northern Tanzania; in International Maize and Wheat Improvement Center (CIMMYT), The United Republic of Tanzania, and the Southern African Center for Cooperation in Agricultural Research (SACCAR). Mexico, 1998, pp 1-16.
25.
Kimanya ME, De Meulenaer B, Tiisekwa B, Ndomondo-Sigonda M, Devlieghere F, Van Camp J, Kolsteren P: Co-occurrence of fumonisins with aflatoxins in home-stored maize for human consumption in rural villages of Tanzania. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2008;25:1353-1364.
26.
Hepworth SJ, Hardie LJ, Fraser LK, Burley VJ, Mijal RS, Wild CP, Azad R, Mckinney PA, Turner PC: Deoxynivalenol exposure assessment in a cohort of pregnant women from Bradford UK. Food Addit Contam 2012;29:269-276.
27.
Amuzie CJ, Pestka JJ: Suppression of insulin-like growth factor acid-labile subunit expression - a novel mechanism for deoxynivalenol-induced growth retardation. Toxicol Sci 2010;113:412-421.
28.
Pestka JJ: Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance. Arch Toxicol 2010;84:663-679.
29.
Goyarts T, Danicke S, Brussow KP, Valenta H, Ueberschar KH, Tiemann U: On the transfer of the Fusarium toxins deoxynivalenol (DON) and zearalenone (ZON) from sows to their foetuses during days 35-70 of gestation. Toxicol Lett 2007;171:38-49.
30.
Hussein HS, Brasel JM: Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology 2001;167:101-134.
31.
Marasas WF: Discovery and occurrence of the fumonisins: a historical perspective. Environ Health Perspect 2001;109:239-243.
32.
FAO/WHO: Fifty-Sixth Report of the Joint FAO/WHO Committee on Food Additives. Evaluation of Certain Mycotoxins in Food. Tech Rep Series No. 906. Geneva, World Health Organization, 2002.
33.
Voss KA, Smith GW, Haschek WM: Fumonisins: toxicokinetics, mechanism of action and toxicity. Anim Feed Sci Technol 2007;137:299-325.
34.
Groopman JD, Kensler TW, Wild CP: Protective interventions to prevent aflatoxin induced carcinogenesis in developing countries. Annu Rev Public Health 2008;29:187-203.
35.
Kimanya ME, De Meulenaer B, Baert K, Tiisekwa B, Van Camp J, Samapundo S, Lachat C, Kolsteren P: Exposure of infants to fumonisins in maize based complementary foods in rural Tanzania. Mol Nutr Food Res 2009;53:667-674.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.